PMID- 38066541
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231209
IS  - 1475-2867 (Print)
IS  - 1475-2867 (Electronic)
IS  - 1475-2867 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Dec 8
TI  - Technical comparison of Abbott's UroVysion((R)) and Biocare's CytoFISH urine 
      fluorescence in situ hybridization (FISH) assays.
PG  - 314
LID - 10.1186/s12935-023-03156-6 [doi]
LID - 314
AB  - BACKGROUND: This study aims to compare the technical performance of Abbott's 
      UroVysion and Biocare's CytoFISH urine cytology probe panel and position the 
      CytoFISH probe panel as an alternative to UroVysion. The CytoFISH probe panel was 
      developed based on clinically sensitive chromosomes found to be amplified in 
      bladder cancers, as well as a locus-specific probe also seen to be amplified in 
      bladder tumors. After extensive testing comparing CytoFISH to UroVysion, we 
      present here our findings for the two assays. MATERIALS AND METHODS: A total of 
      216 cases representing a mix of male (ages 36-99) and female (ages 46-91) 
      patients were assayed with both probe sets. The CytoFISH and UroVysion probe 
      panels were tested in accordance with the UroVysion procedure, as outlined in the 
      manufacturer's supplied package insert with the following exception: the probe 
      volume used was 3microL for UroVysion and 5microL for CytoFISH. RESULTS: The scoring used 
      for the CytoFISH and UroVysion assays revealed a 95% concordance, suggesting that 
      Biocare's CytoFISH Test has at least the same clinical sensitivity and 
      specificity as claimed by the Abbott UroVysion Kit. We found that the CytoFISH 
      5p15.2 locus-specific probe was easier to score than UroVysion's 9p21 deletion. 
      CONCLUSION: The high rate of concordance between the two assays suggests that 
      Biocare's CytoFISH assay is a robust alternative to Abbott's UroVysion in the 
      diagnosis and monitoring of bladder carcinoma.
CI  - (c) 2023. The Author(s).
FAU - Anderson, Tammy
AU  - Anderson T
AD  - Department of Pathology, MidLantic Urology, LLC, 211 South Gulph Road, Suite 211, 
      King of Prussia, PA, 19458, USA.
FAU - Hartman, Sharon
AU  - Hartman S
AD  - Department of Pathology, MidLantic Urology, LLC, 211 South Gulph Road, Suite 211, 
      King of Prussia, PA, 19458, USA. shartman@midlanticurology.com.
FAU - Dunn, William
AU  - Dunn W
AD  - Department of Pathology, MidLantic Urology, LLC, 211 South Gulph Road, Suite 211, 
      King of Prussia, PA, 19458, USA.
FAU - Bellin, Harvey
AU  - Bellin H
AD  - Department of Pathology, MidLantic Urology, LLC, 211 South Gulph Road, Suite 211, 
      King of Prussia, PA, 19458, USA.
FAU - Ehlers, Thomas W
AU  - Ehlers TW
AD  - Biocare Medical, LLC, Concord, CA, USA.
FAU - Groen, Sarah
AU  - Groen S
AD  - Biocare Medical, LLC, Concord, CA, USA.
FAU - Ramos, Jason A
AU  - Ramos JA
AD  - Biocare Medical, LLC, Concord, CA, USA.
LA  - eng
PT  - Journal Article
DEP - 20231208
PL  - England
TA  - Cancer Cell Int
JT  - Cancer cell international
JID - 101139795
PMC - PMC10704636
OTO - NOTNLM
OT  - 5p15.2
OT  - 9p21
OT  - Aneuploidy
OT  - Bladder cancer
OT  - FISH
OT  - Urinary
COIS- The authors declare no competing interests.
EDAT- 2023/12/09 10:46
MHDA- 2023/12/09 10:47
PMCR- 2023/12/08
CRDT- 2023/12/09 00:08
PHST- 2023/03/27 00:00 [received]
PHST- 2023/11/21 00:00 [accepted]
PHST- 2023/12/09 10:47 [medline]
PHST- 2023/12/09 10:46 [pubmed]
PHST- 2023/12/09 00:08 [entrez]
PHST- 2023/12/08 00:00 [pmc-release]
AID - 10.1186/s12935-023-03156-6 [pii]
AID - 3156 [pii]
AID - 10.1186/s12935-023-03156-6 [doi]
PST - epublish
SO  - Cancer Cell Int. 2023 Dec 8;23(1):314. doi: 10.1186/s12935-023-03156-6.